Home About Us Pipeline News Investors Contacts Careers


News

Recent Press Releases Archives

Archives

2023 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011

2021 News Releases

December 10, 2021 - Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting
Read

December 3, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

November 23, 2021 - Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)
Read

November 20, 2021 - Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting
Read

November 19, 2021 - Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
Read

November 4, 2021 - Puma Biotechnology Reports Third Quarter 2021 Financial Results
Read

October 21, 2021 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read

October 6, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

September 21, 2021 - Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference
Read

September 7, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

September 7, 2021 - Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Read

August 6, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

August 5, 2021 - Puma Biotechnology Reports Second Quarter 2021 Financial Results
Read

July 26, 2021 - Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital
Read

July 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read

July 15, 2021 - NCCN Announces Selected Projects to Study Neratinib in Collaboration with Puma Biotechnology, Inc.
Read

July 2, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

July 1, 2021 - FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
Read

June 4, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

June 4, 2021 - Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting
Read

June 4, 2021 - Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting
Read

June 4, 2021 - Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting
Read

May 19, 2021 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting
Read

May 6, 2021 - Puma Biotechnology Reports First Quarter 2021 Financial Results
Read

May 4, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

April 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

April 13, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

March 8, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

March 4, 2021 - Puma Biotechnology to Present at the Barclays Global Healthcare Conference
Read

March 2, 2021 - Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference
Read

February 25, 2021 - Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
Read

February 25, 2021 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read

February 11, 2021 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results
Read

February 9, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

January 29, 2021 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020
Read

January 19, 2021 - Puma Biotechnology to Present at the B. Riley Oncology Investor Conference
Read

January 15, 2021 - Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI
Read

January 5, 2021 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Read

January 4, 2021 - Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference
Read




2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011

Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax